Tokyo, Sept. 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062811) titled 'Treatment Preference Study of Adjuvant Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer' on Sept. 3.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Hormone receptor-positive, HER2-negative early breast cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to quantitatively evaluate the factors prioritized by patients during treatment decision-making in adjuvant endocrine therapy for HR+/HER2- early breast cancer in Japan, as well as t...